阿普斯特能治愈银屑病吗？

Apremilast cannot cure psoriasis, and currently psoriasis cannot be cured. Although a small number of patients do not relapse after effective treatment and achieve clinical cure, the vast majority of patients relapse after remission. Using Apremilast to treat psoriasis can effectively control it and gradually reduce the condition, but it cannot cure it completely.

apster

It is an oral selective gender-specific tyrosine kinase 2 inhibitor that can inhibit cytokine signaling in the pathogenesis of psoriasis and has an intracellular mechanism of action to increase cyclic adenosine monophosphate (cAMP) levels. However, the specific mechanism of its therapeutic effect is not yet clear. It can be used clinically to treat psoriatic arthritis, plaque psoriasis, and oral ulcers related to Behcet's disease.

Apremilast to treat psoriasis

Apremilast's efficacy in moderate to severe psoriasis has been demonstrated in a pivotal trial, with a PASI-75 response rate of 30% at week 16, and this efficacy was sustained through week 52.

In a Phase 3, double-blind, placebo-controlled study, 595 patients with mild-to-moderate psoriasis were randomly assigned to receive 297 apremilast or 298 placebo. A significantly higher static physician-rated global response rate of 21.6% was observed in the apremilast group compared to 4.1% in the placebo group at week 16.

All secondary endpoints were body surface area -75 (33.0% vs. 7.4%), body surface area ≤ 3% (61.0% vs. 22.9%), generalized pruritus numeric rating scale ≥ 4 points (43.2% vs. 18.6%), and scalp physician global assessment of 0 or 1 and ≥ 2 points (44.0% vs. 16.6). %), and changes from baseline in body surface area, psoriasis area and severity index, and dermatology quality of life index (all P < .0001).

In another phase III, multicenter, double-blind, placebo-controlled study, adults were randomized to apremilast or placebo. A total of 844 patients were randomized. At week 16, patients taking apremilast experienced a 75% or greater reduction from baseline in the Psoriasis Area and Severity Index score (PASI-75) compared to the placebo group.

Apostle's

1. Gastrointestinal diseases: gastroesophageal reflux disease, vomiting, upper abdominal pain.

2. Immune system diseases: hypersensitivity reaction.

3. Metabolism and nutritional disorders: decreased adaptability.

4. Nervous system diseases: migraine, headache.

5. Respiratory, thoracic and mediastinal diseases: cough.

6. Skin and subcutaneous tissue diseases: rash.

References:

Stein Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H, Albrecht L, Gooderham M, Chen M, Paris M, Wang Y, Callis Duffin K. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022 Jan;86(1):77-85. doi: 10.1016/j.jaad.2021.07.040. Epub 2021 Jul 31. PMID: 34343599.

Recommended related articles: